Management of antibiotic resistance in the intensive care unit setting

References

• Vincent JL, Sakr Y, Sprung CL et al.; Sepsis Occurrence in Acutely Ill Patients Investigators. Sepsis in European intensive care units: results of the SOAP study. Crit. Care Med.34, 344–353 (2006).
   PubMed Web of Science ®Google Scholar
• Alberti C, Brun-Buisson C, Burchardi H et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med.28, 108–121 (2002).
   PubMed Web of Science ®Google Scholar
• Fridkin SK, Welbel SF, Weinstein RA. Magnitude and prevention of nosocomial infections in the intensive care unit. Infect. Dis. Clin. North Am.11, 479–496 (1997).
   PubMedGoogle Scholar
• Wroblewska MM, Rudnicka J, Marchel H, Luczak M. Multidrug-resistant bacteria isolated from patients hospitalised in intensive care units. Int. J. Antimicrob. Agents27, 285–289 (2006).
   PubMedGoogle Scholar
• Gastmeier P, Sohr D, Geffers C, Behnke M, Rüden H. Risk factors for death due to nosocomial infection in intensive care unit patients: findings from the Krankenhaus Infektions Surveillance System. Infect. Control Hosp. Epidemiol.28, 466–472 (2007).
   PubMed Web of Science ®Google Scholar
• Damas P, Ledoux D, Nys M et al. Intensive care unit acquired infection and organ failure. Intensive Care Med.34, 856–864 (2008).
   PubMedGoogle Scholar
• Brun-Buisson C. ICU-acquired infections and sepsis: more of a deadly duo. Intensive Care Med.34, 793–795 (2008).
   PubMedGoogle Scholar
• Fridkin SK, Steward CD, Edwards JR et al. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE Phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin. Infect. Dis.29, 245–252 (1999).
   PubMed Web of Science ®Google Scholar
• National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am. J. Infect. Control32, 470–485 (2004).
   PubMed Web of Science ®Google Scholar
• Klevens RM, Edwards JR, Tenover FC, McDonald LC, Horan T, Gaynes R; National Nosocomial Infections Surveillance System. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992–2003. Clin. Infect. Dis.42, 389–391 (2006).
   PubMed Web of Science ®Google Scholar
• Gaynes R, Edwards JR; National Nosocomial Infections Surveillance System. Overview of nosocomial infections caused by Gram-negative bacilli. Clin. Infect. Dis.41, 848–854 (2005).
   PubMed Web of Science ®Google Scholar
• Lockhart SR, Abramson MA, Beekmann SE et al. Antimicrobial resistance among Gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004. J. Clin. Microbiol.45, 3352–3359 (2007).
   PubMed Web of Science ®Google Scholar
• Cantón R, Novais A, Valverde A et al. Prevalence and spread of extended-spectrum β-lactamase-producing Enterobacteriaceae in Europe. Clin. Microbiol. Infect.14(Suppl. 1), S144–S153 (2008).
   PubMed Web of Science ®Google Scholar
• Rice LB. The clinical consequences of antimicrobial resistance. Curr. Opin. Microbiol.12, 476–481 (2009).
   PubMed Web of Science ®Google Scholar
• Souli M, Galani I, Giamarellou H. Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill.13(47), ii, 19045 (2008).
   PubMedGoogle Scholar
• Gholizadeh Y, Courvalin P. Acquired and intrinsic glycopeptide resistance in enterococci. Int. J. Antimicrob. Agents.16(Suppl. 1), S11–S17 (2000).
   Google Scholar
• Fish DN, Ohlinger MJ. Antimicrobial resistance: factors and outcomes. Crit. Care Clin.22, 291–311 (2006).
   PubMed Web of Science ®Google Scholar
• Barsanti MC, Woeltje KF. Infection prevention in the intensive care unit. Infect. Dis. Clin. North Am.23, 703–725 (2009).
   PubMed Web of Science ®Google Scholar
• Hidron AI, Edwards JR, Patel J et al.; National Healthcare Safety Network Team; Participating National Healthcare Safety Network Facilities. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007. Infect. Control Hosp. Epidemiol.29, 996–1011 (2008).
   PubMed Web of Science ®Google Scholar
• NNIS System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. Am. J. Infect. Control31, 481–498 (2003).
   PubMed Web of Science ®Google Scholar
• Thompson DS, Workman R, Strutt M. Decline in the rates of methicillin-resistant Staphylococcus aureus acquisition and bacteraemia in a general intensive care unit between 1996 and 2008. J. Hosp. Infect.71, 314–319 (2009).
   PubMedGoogle Scholar
• Burton DC, Edwards JR, Horan TC, Jernigan JA, Fridkin SK. Methicillin-resistant Staphylococcus aureus central line-associated bloodstream infections in US intensive care units, 1997–2007. JAMA301, 727–736 (2009).
   PubMed Web of Science ®Google Scholar
• Pagani L, Falciani M, Aschbacher R. Use of microbiologic findings to manage antimicrobials in the intensive care unit. Infect. Control Hosp. Epidemiol.30, 309–311 (2009).
   PubMedGoogle Scholar
• Theaker C, Ormond-Walsh S, Azadian B, Soni N. MRSA in the critically ill. J. Hosp. Infect.48, 98–102 (2001).
   PubMedGoogle Scholar
• Niven DJ, Laupland KB, Gregson DB, Church DL. The S. aureus screening initiative group. Epidemiology of Staphylococcus aureus nasal colonization and influence on outcome in the critically ill. J. Crit. Care24(4), 583–589 (2009).
   PubMedGoogle Scholar
• Barbarini D, Fumagalli P, Marone P. Methicillin-resistant S. aureus (MRSA) in an intensive care unit: a one year survey. Infez. Med.9, 237–245 (2001).
   PubMedGoogle Scholar
• Tacconelli E, De Angelis G, Cataldo MA et al. Antibiotic usage and risk of colonization and infection with antibiotic-resistant bacteria: a hospital population-based study. Antimicrob. Agents Chemother.53, 4264–4269 (2009).
   PubMed Web of Science ®Google Scholar
• Bloemendaal AL, Fluit AC, Jansen WM et al. Acquisition and cross-transmission of Staphylococcus aureus in European intensive care units. Infect. Control Hosp. Epidemiol.30, 117–124 (2009).
   PubMedGoogle Scholar
• Mayhall CG. Methicillin-resistant Staphylococcus aureus /vancomycin-resistant Enterococci colonization and infection in the critical care unit. In: Infectious Diseases in Critical Care Medicine (2nd Edition). Cunha BA (Ed.). Informa Healthcare, NY, USA (2007).
   Google Scholar
• Thompson DS. Methicillin-resistant Staphylococcus aureus in a general intensive care unit. J. R. Soc. Med.97, 521–526 (2004).
   PubMedGoogle Scholar
• Von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study group. N. Engl. J. Med.344, 11–16 (2001).
   PubMed Web of Science ®Google Scholar
• Tacconelli E, De Angelis G, Cataldo MA et al. Usage of carbapenems significantly increase the rate of new colonisation due to antibiotic-resistant bacteria in hospitalized patients. Presented at: 18th European Congress of Clinical Microbiology and Infectious Diseases. Barcelona, Spain, 19–22 April 2008 (Abstract O395).
   Google Scholar
• Fridkin SK, Edwards JR, Courval JM et al. Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Project and the National Nosocomial Infections Surveillance (NNIS) System Hospitals. The effect of vancomycin and third-generation cephalosporins on prevalence of vancomycin-resistant enterococci in 126 U.S. adult intensive care units. Ann. Intern. Med.135, 175–183 (2001).
   PubMed Web of Science ®Google Scholar
• Deshpande LM, Fritsche TR, Moet GJ, Biedenbach DJ, Jones RN. Antimicrobial resistance and molecular epidemiology of vancomyin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn. Microbiol. Infect. Dis.58, 163–170 (2007).
   PubMed Web of Science ®Google Scholar
• Streit JM, Jones RN, Sader HS, Fritshe TR. Assessment of pathogen occurrences and resistance profiles among infected patients in intensive care unit: report from the SENTRY Antimicrobial Surveillance Program. Int. J. Antimicrob. Agents24, 111–118 (2004).
   PubMed Web of Science ®Google Scholar
• Zirakzadeh A, Patel R. Vancomycin-resistant enterococci: colonization, infection, detection and treatment. Mayo Clin. Proc.81, 529–536 (2006).
   PubMed Web of Science ®Google Scholar
• Leclercq R. Epidemiological and resistance issues in multidrug-resistant staphylococci and enetrococci. Clin. Microbiol. Infect.15, 224–231 (2009).
   PubMed Web of Science ®Google Scholar
• Gould IM. The epidemiology of antibiotic resistance. Int. J. Antimicrob. Agents32(Suppl. 1), S2–S9 (2008).
   PubMed Web of Science ®Google Scholar
• Bryant S, Wilbeck J. Vancomycin-resistant enterococcus in critical care areas. Crit. Care Nurs. Clin. North Am.19, 69–75 (2007).
   PubMedGoogle Scholar
• Burrell LJ, Grabsch EA, Padiglione AA, Grayson ML. Prevalence of colonisation with vancomycin-resistant enterococci (VRE) among haemodyalisis outpatients in Victoria: implications for screening. Med. J. Aus.182, 492 (2005).
   PubMedGoogle Scholar
• Zhanel GG, DeCorby M, Laing N et al. Canadian Antimicrobial Resistance Alliance (CARA). Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005–2006. Antimicrob. Agents Chemother.52, 1430–1437 (2008).
   PubMed Web of Science ®Google Scholar
• Livermore DM, Canton R, Gniadkowski M et al. CTX-M: changing the face of ESBLs in Europe. J. Antimicrob. Chemother.59, 165–174 (2007).
   PubMed Web of Science ®Google Scholar
• Rodríguez-Baño J, Navarro MD, Romero L et al. Epidemiology and clinical features of infections caused by extended-spectrum β-lactamase-producing Escherichia coli in nonhospitalized patients. J. Clin. Microbiol.42, 1089–1094 (2004).
   PubMed Web of Science ®Google Scholar
• March A, Aschbacher R, Dhanji H et al. Colonization of residents and staff of a long-term-care facility and adjacent acute-care hospital geriatric unit by multiresistant bacteria. Clin. Microbiol. Infect. DOI: 10.1111/j.1469-0691. 2009.03024.x (2009) (Epub ahead of print).
   Google Scholar
• Meyer E, Gastmeier P, Schwab F. The burden of multiresistant bacteria in German intensive care units. J. Antimicrob. Chemother.62, 1474–1476 (2008).
   PubMedGoogle Scholar
• Jean SS, Hsueh PR, Lee WS et al. Nationwide surveillance of antimicrobial resistance among non-fermentative Gram-negative bacteria in intensive care units in Taiwan: SMART programme data 2005. Int. J. Antimicrob. Agents33, 266–271 (2009).
   PubMed Web of Science ®Google Scholar
• Munoz-Price LS, Weinstein RA. Acinetobacter infection. N. Engl. J. Med.358, 1271–1281 (2008).
   PubMed Web of Science ®Google Scholar
• Berg DE, Hershow RC, Ramirez CA, Weinstein RA. Control of nosocomial infections in an intensive care unit in Guatemala City. Clin. Infect. Dis.21, 588–593 (1995).
   PubMed Web of Science ®Google Scholar
• Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother.51, 3471–3484 (2007).
   PubMed Web of Science ®Google Scholar
• Maragakis LL, Perl TM. Acinetobacter baumannii : epidemiology, antimicrobial resistance, and treatment options. Clin. Infect. Dis.46, 1254–1263 (2008).
   PubMed Web of Science ®Google Scholar
• Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA289, 885–888 (2003).
   PubMed Web of Science ®Google Scholar
• Karlowsky JA, Draghi DC, Jones ME, Thornsberry C, Friedland IR, Sahm DF. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob. Agents Chemother.47, 1681–1688 (2003).
   PubMed Web of Science ®Google Scholar
• Flamm RK, Weaver MK, Thornsberry C, Jones ME, Karlowsky JA, Sahm DF. Factors associated with relative rates of antibiotic resistance in Pseudomonas aeruginosa isolates tested in clinical laboratories in the United States from 1999 to 2002. Antimicrob. Agents Chemother.48, 2431–2436 (2004).
   PubMed Web of Science ®Google Scholar
• Mendes C, Oplustil C, Sakagami E, Turner P, Kiffer C; MYSTIC Brazil Group. Antimicrobial susceptibility in intensive care units: MYSTIC Program Brazil 2002. Braz. J. Infect. Dis.9, 44–51 (2005).
   PubMedGoogle Scholar
• Obritsch MD, Fish DN, MacLaren R, Jung R. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob. Agents Chemother.48, 4606–4610 (2004).
   PubMed Web of Science ®Google Scholar
• Jones ME, Draghi DC, Thornsberry C, Karlowsky JA, Sahm DF, Wenzel RP. Emerging resistance among bacterial pathogens in the intensive care unit – a European and North American Surveillance study (2000–2002). Ann. Clin. Microbiol. Antimicrob.3, 14 (2004).
   PubMedGoogle Scholar
• Furtado GH, Martins ST, Machado AM, Wey SB, Medeiros EA. Clinical culture surveillance of carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter species in a teaching hospital in Sao Paulo, Brazil: a 7-year study. Infect. Control Hosp. Epidemiol.27, 1270–1273 (2006).
   PubMedGoogle Scholar
• Hanberger H, Arman D, Gill H et al. Surveillance of microbial resistance in European Intensive Care Units: a first report from the Care-ICU programme for improved infection control. Intensive Care Med.35, 91–100 (2009).
   PubMed Web of Science ®Google Scholar
• Miranda MC, Pérez F, Zuluaga T et al. Grupo de Resistencia Bacteriana Nosocomial de Colombia. [Antimicrobial resistance in Gram Negative bacteria isolated from intensive care units of Colombian hospitals, WHONET 2003, 2004 and 2005]. Biomedica26, 424–433 (2006).
   PubMedGoogle Scholar
• Varaiya A, Kulkarni N, Kulkarni M, Bhalekar P, Dogra J. Incidence of metallo β lactamase producing Pseudomonas aeruginosa in ICU patients. Indian J. Med. Res.127, 398–402 (2008).
   PubMedGoogle Scholar
• Lee CY, Chen PY, Huang FL, Lin CF. Microbiologic spectrum and susceptibility pattern of clinical isolates from the pediatric intensive care unit in a single medical center – 6 years’ experience. J. Microbiol. Immunol. Infect.42, 160–165 (2009).
   PubMedGoogle Scholar
• Hsu LY, Tan TY, Jureen R et al. Antimicrobial drug resistance in Singapore hospitals. Emerg. Infect. Dis.13, 1944–1947 (2007).
   PubMed Web of Science ®Google Scholar
• Patzer JA, Dzierzanowska D, Turner PJ. Trends in antimicrobial susceptibility of Gram-negative isolates from a paediatric intensive care unit in Warsaw: results from the MYSTIC programme (1997–2007). J. Antimicrob. Chemother.62, 369–375 (2008).
   PubMedGoogle Scholar
• Madani N, Rosenthal VD, Dendane T, Abidi K, Zeggwagh AA, Abouqal R. Health-care associated infections rates, length of stay, and bacterial resistance in an intensive care unit of Morocco: findings of the International Nosocomial Infection Control Consortium (INICC). Int. Arch. Med.2, 29 (2009).
   PubMedGoogle Scholar
• Merrer J, Santoli F, Appéré de Vecchi C, Tran B, De Jonghe B, Outin H. “Colonization pressure” and risk of acquisition of methicillin-resistant Staphylococcus aureus in a medical intensive care unit. Infect. Control Hosp. Epidemiol.21, 718–723 (2000).
   PubMed Web of Science ®Google Scholar
• Siegel JD, Rhinehart E, Jackson M, Chiarello L; Healthcare Infection Control Practices Advisory Committee. Management of multidrug-resistant organisms in health care settings, 2006. Am. J. Infect. Control.35(10 Suppl. 2), S165–S193 (2007).
   PubMed Web of Science ®Google Scholar
• Bhalla A, Pultz NJ, Gries DM et al. Acquisition of nosocomial pathogens on hands after contact with environmental surfaces near hospitalized patients. Infect. Control Hosp. Epidemiol.25, 164–167 (2004).
   PubMed Web of Science ®Google Scholar
• Pittet D, Allegranzi B, Boyce J; World Health Organization World Alliance for Patient Safety First Global Patient Safety Challenge Core Group of Experts. The World Health Organization Guidelines on Hand Hygiene in Health Care and their consensus recommendations. Infect. Control Hosp. Epidemiol.30, 611–622 (2009).
   PubMed Web of Science ®Google Scholar
• Popovich KJ, Hota B, Hayes R, Weinstein RA, Hayden MK. Effectiveness of routine patient cleansing with chlorhexidine gluconate for infection prevention in the medical intensive care unit. Infect. Control Hosp. Epidemiol.30, 959–963 (2009).
   PubMed Web of Science ®Google Scholar
• Talbot GH, Bradley J, Edwards JE Jr, Gilbert D, Scheld M, Bartlett JG. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin. Infect. Dis.42, 657–668 (2006).
   PubMed Web of Science ®Google Scholar
• Bassetti M, Cruciani M, Righi E et al. Antimicrobial use and resistance among Gram-negative bacilli in an Italian intensive care unit (ICU). J. Chemother.18, 261–267 (2006).
   PubMed Web of Science ®Google Scholar
• Tsai HT, Wang JT, Chen CJ, Chang SC. Association between antibiotic usage and subsequent colonization or infection of extensive drug-resistant Acinetobacter baumannii : a matched case – control study in intensive care units. Diagn. Microbiol. Infect. Dis.62, 298–305 (2008).
   PubMedGoogle Scholar
• Ibrahim EH, Tracy L, Hill C, Fraser VJ, Kollef MH. The occurrence of ventilator-associated pneumonia in a community hospital: risk factors and clinical outcomes. Chest120, 555–561 (2001).
   PubMed Web of Science ®Google Scholar
• Chastre J. Ventilator-associated pneumonia: what is new? Surg. Infect. (Larchmt).7(Suppl. 2), S81–S85 (2006).
   Google Scholar
• Chastre J, Wolff M, Fagon JY et al. Comparison of 8 vs. 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA290, 2588–2598 (2003).
   PubMed Web of Science ®Google Scholar
• Grammatikos AP, Siempos II, Michalopoulos A, Falagas ME. Optimal duration of the antimicrobial treatment of ventilator-acquired pneumonia. Expert Rev. Anti Infect. Ther.6, 861–866 (2008).
   PubMed Web of Science ®Google Scholar
• Hedrick TL, McElearney ST, Smith RL, Evans HL, Pruett TL, Sawyer RG. Duration of antibiotic therapy for ventilator-associated pneumonia caused by non-fermentative Gram-negative bacilli. Surg. Infect. (Larchmt).8, 589–597 (2007).
   PubMedGoogle Scholar
• Hoffken G, Niederman MS. Nosocomial pneumonia: the importance of a deescalating strategy for antibiotic treatment of pneumonia in the ICU. Chest122, 2183–2196 (2002).
   PubMed Web of Science ®Google Scholar
• Kollef MH, Sherman G, Ward S, Fraser V. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest115, 462–474 (1999)
   PubMed Web of Science ®Google Scholar
• Luna CM, Vujacich P, Niederman MS et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest111, 676–685 (1997).
   PubMed Web of Science ®Google Scholar
• Tellado JM, Sen SS, Caloto MT, Kumar RN, Nocea G. Consequences of inappropriate initial empiric parenteral antibiotic therapy among patients with community-acquired intra-abdominal infections in Spain. Scand. J. Infect. Dis.39, 947–955 (2007).
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Sali M, Trecarichi EM et al. Bloodstream infections caused by extended-spectrum-β-lactamase-producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy. Antimicrob. Agents Chem.52, 3244–3252 (2008).
   PubMed Web of Science ®Google Scholar
• MacDougall C, Polk RE. Antimicrobial stewardship programs in healthcare systems. Clin. Microbiol. Rev.18, 638–656 (2005).
   PubMed Web of Science ®Google Scholar
• Lesprit P, Brun-Buisson C. Hospital antibiotic stewardship. Curr. Opin. Infect. Dis.21, 344–349 (2008).
   PubMedGoogle Scholar
• Owens RC. Antimicrobial stewardship: application in the intensive care. Infect. Dis. Clin. N. Am.23, 683–702 (2009).
   PubMedGoogle Scholar
• Lawrence KL, Kollef MH. Antimicrobial stewardship in the intensive care unit. Advances and obstacles. Am. J. Respir. Crit. Care. Med.179, 434–438 (2009).
   PubMed Web of Science ®Google Scholar
• Thursky KA, Buising KL, Bak N et al. Reduction of broad-spectrum antibiotic use with computerized decision support in an intensive care unit. Int. J. Qual. Health Care18, 224–231 (2006).
   PubMedGoogle Scholar
• Thiel SW, Asghar MF, Micek ST, Reichley RM, Doherty JA, Kollef MH. Hospital-wide impact of a standardized order set for the management of bacteremic severe sepsis. Crit. Care Med.37, 819–824 (2009).
   PubMed Web of Science ®Google Scholar
• Raineri E, Pan A, Mondello P, Acquarolo A, Candiani A, Crema L. Role of the infectious diseases specialist consultant on the appropriateness of antimicrobial therapy prescription in an intensive care unit. Am. J. Infect. Control36, 283–290 (2008).
   PubMed Web of Science ®Google Scholar
• Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am. J. Respir. Crit. Care Med.177, 498–505 (2008).
   PubMed Web of Science ®Google Scholar
• Rahal JJ. Antimicrobial resistance among therapeutic options against Gram-negative pathogens. Clin. Infect. Dis.49(Suppl. 1), S4–S10 (2009).
   PubMed Web of Science ®Google Scholar
• Paul MP, Leibovici L. Combination antimicrobial treatment versus monotherapy: the contribution of meta-analyses. Infect. Dis. Clin. N. Am.23, 277–293 (2009).
   PubMed Web of Science ®Google Scholar
• Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect. Dis.4, 519–527 (2004).
   PubMed Web of Science ®Google Scholar
• Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L. β lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. Br. Med. J.328, 668 (2004).
   PubMed Web of Science ®Google Scholar
• Paul M, Silbiger I, Grozinsky S, Soares-Weiser K, Leibovici L. β lactam antibiotic monotherapy versus β lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst. Rev.CD003344 (2006).
   PubMedGoogle Scholar
• Aarts MA, Hancock JN, Heyland D et al. Empiric antibiotic therapy for suspected ventilator-associated pneumonia: a systematic review and meta-analysis of randomized trials. Crit. Care Med.36, 108–117 (2008).
   PubMed Web of Science ®Google Scholar
• Micek ST, Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob. Agents Chemother.49, 1306–1311 (2005).
   PubMed Web of Science ®Google Scholar
• Tam VH, Gamez EA, Weston JS, Gerard LN, La Rocco MT, Caeiro JP. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin–tazobactam: implications on the appropriateness of the resistance breakpoint. Clin. Infect. Dis.46, 862–867 (2008).
   PubMed Web of Science ®Google Scholar
• Badal R, Bouchillon S, Hawser S et al. Impact of different EUCAST and CLSI interpretive breakpoints on antimicrobial susceptibility of Pseudomonas aeruginosa SMART2007. Presented at: 19th European Congress of Microbiology and Infectious Diseases. Helsinki, Finland, 16–19 May 2009 (Abstract P818).
   Google Scholar
• Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America; American Thoracic Society. Consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis.44(Suppl. 2), S27–S72 (2007).
   PubMed Web of Science ®Google Scholar
• Bassetti M, Righi E, Viscoli C. Pseudomonas aeruginosa serious infections: mono or combination antimicrobial therapy. Curr. Med. Chem.15, 517–522 (2008).
   PubMed Web of Science ®Google Scholar
• Morse PA, North N, Steenbergen JN, Sakoulas G. Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus : facts and assumption. Lancet Infect. Dis.9, 617–624 (2009).
   PubMedGoogle Scholar
• Moise PA, Sakoulas G, Forrest A, Schentag JJ. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother.51, 2582–2586 (2007).
   PubMed Web of Science ®Google Scholar
• Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol.42, 2398–2402 (2004).
   PubMed Web of Science ®Google Scholar
• Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC Jr. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin. Infect. Dis.38, 1700–1705 (2004).
   PubMed Web of Science ®Google Scholar
• Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch. Intern. Med.166, 2138–2144 (2006).
   PubMed Web of Science ®Google Scholar
• Maclayton DO, Suda KJ, Coval KA, York CB, Garey KW. Case–control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2µg/ml and risk factors, costs, and outcomes in inpatients undergoing hemodialysis. Clin. Ther.28, 1208–1216 (2006).
   PubMed Web of Science ®Google Scholar
• Soriano A, Marco F, Martinez JA et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis.46, 193–200 (2008).
   PubMed Web of Science ®Google Scholar
• Lodise TP, Graves J, Evans A et al. Relationship between vancomycin MIC and failure among patients with methicillin resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob. Agents Chemother.52, 3315–3320 (2008).
   PubMed Web of Science ®Google Scholar
• Howden BP, Ward PB, Charles PG et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin. Infect. Dis.38, 521–528 (2004).
   PubMed Web of Science ®Google Scholar
• Szabó J. hVISA/VISA: diagnostic and therapeutic problems. Expert Rev. Anti Infect. Ther.7, 1–3 (2009).
   PubMed Web of Science ®Google Scholar
• Tenover FC, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin. Infect. Dis.44, 1208–1215 (2007).
   PubMed Web of Science ®Google Scholar
• Price J, Atkinson S, Llewelyn M, Paul J. Paradoxical relationship between the clinical outcome of Staphylococcus aureus bacteremia and the minimum inhibitory concentration of vancomycin. Clin. Infect. Dis.48, 996–997 (2009).
   PubMedGoogle Scholar
• Soriano A, Martinez JA, Mensa J. Reply to Price et al. and to Pea and Viale. Clin. Infect. Dis.49, 643–645 (2009).
   Google Scholar
• Pea F, Viale P. Is the minimum inhibitory concentration of vancomycin an infallible predictor of the clinical outcome of Staphylococcus aureus bacteremia treated with vancomycin? Clin. Infect. Dis.49, 642–643 (2009).
   PubMedGoogle Scholar
• Pea F, Viale P. The antimicrobial therapy puzzle: could pharmacokinetic–pharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients? Clin. Infect. Dis.42, 1764–1771 (2006).
   PubMed Web of Science ®Google Scholar
• Wysocki M, Delatour F, Faurisson F et al. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrob. Agents Chemother.45, 2460–2467 (2001).
   PubMed Web of Science ®Google Scholar
• Pea F, Furlanut M, Negri C et al. Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in the critically ill patients: the Optivanco study. Antimicrob. Agents Chemother.53, 1863–1867 (2009).
   PubMed Web of Science ®Google Scholar
• Roberts JA, Lipman J, Blot S, Rello J. Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients? Curr. Opin. Crit. Care.14, 390–396 (2008).
   PubMed Web of Science ®Google Scholar
• Rello J, Sole-Violan J, Sa-Borges M et al. Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides. Crit. Care Med.33, 1983–1987 (2005).
   PubMed Web of Science ®Google Scholar
• Rybak MJ, Lomaestro BM, Rotschafer JC et al. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of health-system pharmacists, the infectious diseases society of America, and the society of infectious diseases pharmacists. Pharmacotherapy29, 1275–1279 (2009).
   PubMed Web of Science ®Google Scholar
• Rybak MJ, Lomaestro BM, Rotscahfer JC et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists and the Society of Infectious Diseases Pharmacists. Clin. Infect. Dis.49, 325–327 (2009).
   PubMed Web of Science ®Google Scholar
• Nation RL, Li J. Colistin in the 21st Century. Curr. Opin. Infect. Dis.22, 535–543 (2009).
   PubMed Web of Science ®Google Scholar
• El Solh AA, Alhajhusain A. Update on the treatment of Pseudomonas aeruginosa pneumonia. J. Antimicrob. Chemother.64, 229–238 (2009).
   PubMed Web of Science ®Google Scholar
• Pea F, Viale P. Bench-to-bedside review: appropriate antibiotic therapy in severe sepsis and septic shock – does the dose matter? Crit. Care13, 214 (2009).
   PubMed Web of Science ®Google Scholar